CIP
VNDA icon

Convergence Investment Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Convergence Investment Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,972
Closed -$220K – 391
2019
Q1 		$220K Buy
+11,972
New +$273K 0.05% 261
2018
Q4 		– Sell
-12,489
Closed -$287K – 375
2018
Q3 		$287K Buy
+12,489
New +$255K 0.06% 274

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Convergence Investment Partners's VNDA Position: Q2 2019 in Review

Convergence Investment Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 11,972 shares — an estimated $220K sold.

Convergence Investment Partners first reported a position in VNDA in Q3 2018 and held it in 2 quarters. The position peaked at $287K in Q3 2018. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Convergence Investment Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 11,972 Vanda Pharmaceuticals shares in Q2 2019, an estimated $220K.
  • Convergence Investment Partners first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Convergence Investment Partners's Vanda Pharmaceuticals position peaked at $287K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Convergence Investment Partners's 13F filing for Q2 2019, filed 23 Jul 2019.